Nemaura Medical Inc. (NMRD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Visitors trend2W10W9M

2.1408

+0.0308

(+1.46%)

At close: 11:35AM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	2.1100
Open	2.1408
Bid	1.8000 x 4000
Ask	2.2600 x 800
Day's Range	2.1408 - 2.2000
52 Week Range	1.5000 - 5.9400
Volume	523
Avg. Volume	10,461

Market Cap	51.6M
Beta (5Y Monthly)	0.00
PE Ratio (TTM)	N/A
EPS (TTM)	-0.5350
Earnings Date	Feb 09, 2023 - Feb 13, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	9.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NMRD

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Nemaura Medical Inc.
DXCM: Lowering target price to $117.00DEXCOM INC has an Investment Rating of HOLD; a target price of $117.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

GlobeNewswire
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022. Presentation Date: December 7, 2022Time: 9:00am ESTWebcast Link: https://www.w
- Navitas to Participate in China Renaissance, Fubon Securities, and CICC Investor Meetings
  GlobeNewswire
- Enerpac Tool Group Schedules First Quarter Fiscal 2023 Earnings Conference Call
  Business Wire
GlobeNewswire
Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that it has commenced patient studies of its proprietary metabolic health program, Miboko, with the National Health Service (NHS) in the United Kingdom. Miboko, is the first metabolic tracking pr
Zacks
Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?